Keywords: fillip, biogen, fda, sets, new, trial, requirement
Fillip for Biogen as FDA sets no new trial requirement for Amevive
Article | 24 June 2002
Biogen moved a step closer towards US approval of its new treatment formoderate-to-severe chronic plaque psoriasis, Amevive (alefacept), with the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
